As the biologics landscape grows increasingly complex, CDMOs are under pressure to deliver more than additional manufacturing capacity. Emerging biotechs and established innovators alike are seeking partners capable of integrating development, analytics, manufacturing, quality, and regulatory expertise into a seamless pathway from discovery through commercialization. In this exclusive BioPharma Boardroom interview, Uday Hardikar, Site Head for Bristol, and Sean O'Brien, COO and Site Head for San Diego at Abzena, explore how engineering-led expansion strategies, digital transformation, and cross-functional collaboration are redefining CDMO value. They discuss how investments in infrastructure, talent, and operational excellence translate into faster project starts, improved CMC continuity, and stronger outcomes for developers of complex biologics and conjugates.

As CDMO expansions accelerate globally, what do investments in commercial growth actually translate to in day-to-day operations for biotech clients?

Uday Hardikar

For biotech clients, investments in CDMO commercial growth should translate into something very tangible: confidence that their program can move faster without losing scientific or operational discipline. At the day-to-day level, clients are not just looking for more suites, more tanks, or more square footage. They are looking for a partner who can help them make better decisions earlier, remove friction between development and manufacturing, and keep momentum as the program advances toward the clinic and, ultimately, commercialization.

In practice, that means the CDMO must be able to bring the right people together quickly — process development, analytical development, manufacturing, quality, engineering, supply chain, and program management — around one integrated plan. For complex biologics and bioconjugates, success depends on how well those functions work together. A strong process is not developed in isolation. It must be supported by robust analytical methods, clear product understanding, practical manufacturing input, and a tech transfer strategy that begins early rather than at the end of development.

The real value of expansion is therefore not simply increased capacity; it is increased execution readiness. To do this well, companies need to avoid the false tradeoff between speed and rigor. Speed comes from integration, preparation, and disciplined execution — not from cutting corners. Clients should see benefits in faster project initiation, clearer technical plans, fewer handoffs, and earlier identification of risks that could otherwise delay manufacturing or regulatory progress. When development, analytics, and manufacturing are aligned from the start, companies can accelerate time to market while still building a process that is scalable, well-characterized, and capable of supporting high-confidence clinical and commercial supply.

For emerging biotechs especially, this is where an integrated CDMO can create significant value. Many smaller companies lack the internal infrastructure to build every CMC capability themselves. What they need is a partner who can translate promising science into an executable development and manufacturing pathway — one that balances urgency with quality, and speed with long-term program success. At Abzena, this aligns closely with the focus on integrated early R&D through commercial capabilities, high-quality trusted data, streamlined regulatory support, minimized tech-transfer redundancy, parallel workstreams, standardized platforms, and interconnected technical teams.

Ultimately, commercial growth investments matter most when they help clients move with greater certainty. The best expansions do not just add capacity; they create a more connected, technically capable, and reliable operating model. For biotech clients, that translates into fewer surprises, stronger CMC continuity, and greater confidence that their molecule can move from development to patients as efficiently and responsibly as possible.

Sean O'Brien  

For clients, it's not really about the footprint, it's about whether their program runs the way it's supposed to. At Abzena, for example, our recent facility investments have been less about adding space and more about strengthening teams, improving planning discipline, and building systems that can handle variability. Day-to-day, that shows up as fewer surprises—whether that's smoother tech transfers or more predictable batch execution. Most clients aren't focused on square footage—they're focused on whether you can execute when it counts.

Beyond increased capacity, how do site expansions enable faster project initiation and reduce common development or manufacturing bottlenecks?

Uday Hardikar

Site expansions create the most value when they are designed around how programs actually move — from development to analytics to tech transfer to GMP manufacturing. So, when building new capacity, companies should consider design for flexibility from the start. Flexible, multipurpose manufacturing systems allow CDMOs to support different molecule types, scales, and program phases without requiring major reconfiguration each time.

But when it comes to faster project initiation, it's not just the physical capacity; it is faster alignment of the right teams and fewer delays between critical stages.

Many bottlenecks occur when development decisions are made without early input from analytical, manufacturing, quality, and engineering teams. Companies can accelerate timelines by using scalable technologies from the start, selecting development equipment and unit operations that better reflect the intended GMP process, and applying single-use technologies where they improve flexibility, reduce the cleaning validation burden, and enable faster campaign changeover.

Equally important is early engagement in analytics and manufacturing. Robust process analytical tools, phase-appropriate methods, and early product understanding help teams make better decisions and reduce surprises during scale-up. Tech transfer should also begin early as a structured, cross-functional activity, rather than a handoff at the end of development.

For complex biologics and conjugates, this integrated approach is critical. When process development, analytical development, manufacturing, quality, and tech transfer are connected from the beginning, companies can move faster while still building scalable processes, robust methods, reduced validation complexity, and high confidence in GMP execution.

Sean O'Brien  

The most effective expansions don't just add square footage, they address constraints across the entire workflow. At Abzena, we've been deliberate about building out analytical, process development, and project management capabilities alongside capacity. Equally important, we've strengthened supply chain and integrated planning from support functions into core strategic capabilities.

That distinction matters because the most common delays don't come from lab capacity—they come from material readiness, scheduling gaps, or lack of alignment across teams. By tightening planning and integrating supply chain earlier in the process, we're able to line up materials, resources, and timelines more proactively.

A good example is tech transfer into GMP. In the past, you'd often see delays where documentation, materials, or analytical readiness lagged manufacturing scheduling. With stronger planning and coordination across functions, we're now able to bring those elements together earlier—when a batch window opens, everything is ready to go. Combined with broader technical capabilities, that allows more overlap between activities rather than a strictly sequential process.

The result is faster project starts, fewer last-minute bottlenecks, and a more predictable path through development and manufacturing.

How are infrastructure and engineering upgrades improving quality, reliability and overall CMC continuity across programs?

Uday Hardikar

Infrastructure and engineering upgrades are central to quality and CMC continuity because they create the conditions for repeatable execution. In a CDMO environment, quality is not only a function of procedures; it is also a function of facility design, utilities, material/personnel flows, equipment fit, contamination control strategy, automation, data integrity, and maintainability.

When engineering is integrated early into expansion planning, facilities can be designed to support how programs actually move through development and manufacturing. This includes appropriate segregation, scalable equipment trains, fit-for-purpose utilities, analytical and QC support, stability infrastructure, and layouts that reduce unnecessary movement or complexity. These upgrades improve reliability by reducing variability and by making it easier for teams to execute the same process in a consistent, compliant manner.

From a CMC perspective, continuity is achieved when the development history, analytical strategy, process understanding, and manufacturing control strategy remain connected. Upgraded infrastructure supports that continuity by allowing processes to scale without unnecessary rework and by ensuring that analytical, quality, and manufacturing capabilities are aligned with the needs of the molecule at each phase.

Sean O'Brien 

A lot of this comes down to consistency and visibility. Investments we've made at Abzena in automation, digital systems, and facility infrastructure have helped standardize how processes are run and monitored. That reduces variability and makes it easier to identify issues early. From a client perspective, it translates to more reliable execution and greater confidence that a process developed during early phases will scale-up successfully into GMP manufacturing. When these systems are working well, they're largely invisible—but they're what underpin CMC continuity.

From your perspective, what differentiates truly integrated, engineering-led CDMO growth from more traditional expansion strategies?

Uday Hardikar

Traditional expansion often starts with capacity — adding suites, equipment, and headcount — and then determining how programs will fit. Truly integrated, engineering-led growth starts with the molecule, the process, the client journey, and the CMC risks, then builds the infrastructure, talent model, and operating system around those needs.

The key difference is that integrated growth creates capacity that is not only larger, but more usable, flexible, and reliable. It considers where tech transfers fail, where analytical decisions affect manufacturing success, and how material, personnel, data, quality, and manufacturing flows should be designed to support speed and compliance.

Talent is central to this model. Strong scientific and technical experts, supported by agile and adaptable teams, help clients solve problems quickly, make better decisions earlier, and maintain momentum as programs evolve. For complex biologics and conjugates, this flexibility is critical because development rarely moves in a straight line.

A true one-stop-shop CDMO also reduces handoffs by connecting development, analytics, manufacturing, quality, regulatory, and tech transfer under one coordinated model. The value is not simply having all capabilities available; it is making sure they work together seamlessly around the client's molecule.

Ultimately, integrated, engineering-led growth is about more than adding capacity. It is about building a technically excellent, flexible, and client-focused organization that can translate complex science into reliable execution from development through clinical and commercial supply.

Sean O'Brien 

For us, it starts with designing for execution, not just capacity. Engineering-led growth at Abzena has meant integrating engineering, operations, quality, supply chain, and technical development, particularly as we've expanded capabilities for more complex modalities like ADCs and AOCs. That alignment reduces the friction you typically see at handoffs and allows decisions to be made faster. In practice, clients experience it as a smoother tech transfer, with clearer accountability, and fewer delays tied to cross-functional gaps.

How can smaller or emerging biotechs best evaluate whether a CDMO's expanded capabilities will meaningfully impact their timelines and outcomes?

Uday Hardikar

Smaller and emerging biotechs should look beyond the headline capacity announcement and ask how the expansion changes execution for their specific program. The key question is not "Do you have capacity?" but "How will this capability reduce risk, shorten decision cycles, and improve the probability of technical and regulatory success for my molecule?"

I would encourage emerging biotechs to evaluate five areas. First, integration: can the CDMO connect discovery, development, analytics, manufacturing, quality, and regulatory support without repeated handoffs? Second, technical depth: do they have real experience with the modality and the specific complexity of the product? Third, readiness: are the people, systems, quality processes, and engineering controls in place, or is the expansion still theoretical? Fourth, governance: is there a clear program structure with transparent decision-making and escalation? Fifth, data quality: will the CDMO generate the type of trusted, phase-appropriate data needed for downstream CMC decisions?

For complex biologics and bioconjugates, clients should also ask how process development, analytical characterization, and manufacturing scale-up are connected. A CDMO's expanded capability is meaningful only if it improves the path from scientific idea to a manufacturable, controllable, and clinically relevant product.

Sean O'Brien 

I'd focus less on the messaging and more on how the organization performs. With Abzena, for instance, we tend to walk clients through specific examples—how expansions have improved tech transfer timelines, increased batch success rates, or improved responsiveness when issues arise. That's where you get a clearer picture of whether the investment translated into better execution. Facilities matter, but it's the combination of people, systems, and processes that ultimately determines outcomes.

Looking ahead, how do you see CDMO expansion strategies evolving to better support complex biologics and conjugates?

Uday Hardikar

CDMO expansion strategies will need to become more specialized, integrated, and technology-enabled. The next wave of growth will not be about adding generic biologics capacity alone; it will be about building capabilities designed for complex modalities such as ADCs, AOCs, bispecifics, novel conjugates, and other products where chemistry, biology, analytics, engineering, and manufacturing are tightly connected.

Successful CDMOs will increasingly leverage innovation in technology to drive better process understanding, scalability, and predictability. Advanced analytical tools, process analytical technologies, digital systems, automation, and data-driven decision-making can help teams understand processes earlier, reduce variability, and improve confidence during scale-up and tech transfer.

I also believe the future will require stronger convergence of science, engineering, technology, and IT. Complex programs cannot be supported effectively through siloed functions. Development teams, analytical scientists, manufacturing experts, engineers, quality, and digital/IT teams need to work together from the beginning to create scalable processes, robust control strategies, and reliable execution pathways.

Flexible manufacturing systems will also be essential. CDMOs will need multipurpose, adaptable facilities that can support different molecule types, batch sizes, and development phases without major reconfiguration. This flexibility will help clients move faster as program needs evolve.

Finally, CDMOs can benefit from more agile ways of working, including scrum-style development approaches where cross-functional teams operate in focused, iterative cycles. This allows faster problem solving, earlier risk identification, and better alignment across process development, analytical development, manufacturing, quality, and tech transfer.

Ultimately, the most effective expansion strategies will not simply add capacity. They will combine scientific excellence, engineering discipline, flexible manufacturing, digital capability, and agile execution to reduce CMC risk and help clients move complex biologics and conjugates from development to patients with greater confidence.

Sean O'Brien  

As programs get more complex, flexibility and integration will become even more important. At Abzena, we're already seeing that with conjugates and other advanced biologics, where success depends on how well development, analytics, and manufacturing are connected. I expect continued investment in digital tools, automation, and specialized technical expertise to support that complexity. Going forward, the differentiator will be CDMOs that can combine that technical depth with consistently reliable execution across the product lifecycle.